The role of neoantigens in response to immune checkpoint blockade Journal Article


Authors: Riaz, N.; Morris, L.; Havel, J. J.; Makarov, V.; Desrichard, A.; Chan, T. A.
Article Title: The role of neoantigens in response to immune checkpoint blockade
Abstract: Immune checkpoint blockade has demonstrated substantial promise for the treatment of several advanced malignancies. These agents activate the immune system to attack tumor cells. For example, agents targeting CTLA4 and programmed cell death 1 (PD-1) have resulted in impressive response rates and, in some cases, durable remissions. Neoantigens are mutations that encode immunologically active proteins that can cause the immune system to recognize the affected cell as foreign. Recent data have made it clear that these mutations are, in large part, the functional targets of immune checkpoint blockade. This review summarizes the key discoveries leading up to this important conclusion and discusses possible applications of neoantigens in cancer therapy. © The Japanese Society for Immunology. 2016. All rights reserved.
Keywords: mutation; immunotherapy; cancer; neoantigen
Journal Title: International Immunology
Volume: 28
Issue: 8
ISSN: 0953-8178
Publisher: Oxford University Press  
Date Published: 2016-08-01
Start Page: 411
End Page: 419
Language: English
DOI: 10.1093/intimm/dxw019
PROVIDER: scopus
PMCID: PMC4986233
PUBMED: 27048318
DOI/URL:
Notes: Article -- Export Date: 2 November 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Timothy Chan
    317 Chan
  2. Nadeem Riaz
    415 Riaz
  3. Luc Morris
    278 Morris
  4. Vladimir Makarov
    57 Makarov
  5. Jonathan Joseph Havel
    18 Havel